Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $210 million, exceeding the high end of the pre-announced range, with a year-over-year growth of approximately 4% when excluding the impact from UnitedHealthcare's decision on GeneSight [6][25] - For the full year 2025, revenue was $824.5 million, with adjusted EBITDA of $14.3 million and adjusted EPS of $0.04, reflecting strong operational performance [8][28] - Adjusted gross margin for the fourth quarter was 70%, with adjusted operating expenses decreasing by $7 million year-over-year due to disciplined cost management [8][27] Business Line Data and Key Metrics Changes - Oncology revenue for the fourth quarter was $84.7 million, growing 2% year-over-year, with MyRisk test volume growth of 14% in the affected market and 11% in the unaffected market [16][18] - Prolaris revenue growth accelerated to 16% year-over-year in the fourth quarter, driven by 12% volume growth [16][17] - Women's health revenue was $88.5 million, an increase of 2% year-over-year, with hereditary cancer testing in the unaffected market growing by 3% and volume growth of 11% [18][19] - GeneSight revenue was $36.6 million, with volume growth of 9% year-over-year, despite challenges from UnitedHealthcare's coverage policy change [22][24] Market Data and Key Metrics Changes - The company served over 55,000 healthcare providers and delivered over 1.5 million test reports in 2025, indicating strong market penetration [8] - The mental health business saw a record number of ordering clinicians, exceeding 38,000 in the fourth quarter [22] Company Strategy and Development Direction - The company is focusing on high-growth market segments and plans multiple product launches, including the expanded MyRisk panel and the AI-enhanced Prolaris test [5][10] - The strategy includes strengthening commercial capabilities and expanding the sales team, with an investment of over $35 million to enhance organizational efficiency and growth [15][61] - The company aims to maintain leadership in urinary cancer testing while expanding into other cancer testing applications [9][33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving high single-digit to low double-digit growth rates in 2027 and beyond, supported by new product launches and recovery in the prenatal business [39][40] - The company is optimistic about the potential for continued momentum in hereditary cancer testing and prenatal testing, with expectations for recovery in 2026 [20][21] Other Important Information - The company plans to simplify its reporting structure to align with its strategic focus areas, including cancer care continuum, prenatal health, and mental health [31][32] - The company is preparing for the commercial launch of Precise MRD for breast cancer, with an alpha launch starting next week [11][14] Q&A Session Summary Question: Confidence in long-term growth rate - Management highlighted the drivers of growth for 2026, including product launches and improvements in commercial execution, expressing confidence in returning to high single-digit growth rates [37][39] Question: MRD launch strategy - Management indicated a selective approach for the MRD launch, focusing on user experience and operational efficiency before expanding volume [40][42] Question: Prenatal growth expectations - Management acknowledged a decline in prenatal volume in Q1 but anticipated recovery in Q2 and beyond, supported by a focused sales team and new product launches [45][81] Question: Prolaris momentum and dynamics - Management noted that improved engagement with KOLs and expansion of the sales team contributed to Prolaris growth, while also acknowledging potential favorable comparisons in Q4 [74][76] Question: Customer impact from order management issues - Management emphasized the importance of addressing order management issues and expressed confidence in restoring customer relationships and achieving growth moving forward [86][88]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $210 million, exceeding the high end of the pre-announced range, with a year-over-year growth of approximately 4% when excluding the impact from UnitedHealthcare's decision on GeneSight [6][25] - For the full year 2025, revenue was $824.5 million, with adjusted EBITDA of $14.3 million and adjusted EPS of $0.04, reflecting disciplined cost management and strategic investments [8][28] - The adjusted gross margin for the fourth quarter was 70%, down approximately 190 basis points year-over-year due to the revenue headwind from GeneSight [9][26] Business Line Data and Key Metrics Changes - Oncology revenue for the fourth quarter was $84.7 million, with MyRisk test volume growth of 14% in the affected market and 11% in the unaffected market [16][18] - Prolaris revenue growth accelerated to 16% year-over-year in the fourth quarter, driven by a 12% increase in test volume [16][17] - Women's health revenue was $88.5 million, reflecting a 2% increase year-over-year, with hereditary cancer testing in the unaffected market growing by 3% and volume growth of 11% [18][19] Market Data and Key Metrics Changes - GeneSight volume grew 9% year-over-year, with a record number of ordering clinicians reaching over 38,000 [22] - The company faced challenges in prenatal testing, with a decline in volume due to order management disruptions, but expects recovery in 2026 [21][22] - The mental health segment showed resilience, with GeneSight revenues impacted by UnitedHealthcare's coverage policy change but still achieving positive coverage policies across 12 payers [23] Company Strategy and Development Direction - The company is focusing on high-growth market segments and plans multiple product launches, including the expanded MyRisk panel and the AI-enhanced Prolaris test [5][10] - A significant investment of over $35 million is planned to enhance organizational efficiency and commercial capabilities, particularly in the cancer care continuum [15][60] - The company aims to strengthen its position across cancer care testing while leveraging operational strengths for sample processing and reporting [33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving high single-digit to low double-digit growth rates in 2027 and beyond, driven by new product launches and recovery in the prenatal business [39] - The company is optimistic about the potential for continued momentum in hereditary cancer testing and expects to regain share in the prenatal market [20][21] - Management emphasized the importance of execution excellence and rigorous testing before launching new products to avoid past issues [82] Other Important Information - The company plans to simplify its reporting structure to align with its refreshed strategy, focusing on cancer care continuum, prenatal health, and mental health as distinct categories [31] - The company maintains a solid balance sheet with access to $225 million in capital and intends to file a universal shelf registration [28] Q&A Session Summary Question: Confidence in long-term growth rate - Management highlighted several growth drivers for 2026, including product launches and improvements in commercial execution, expressing confidence in returning to high single-digit growth rates [38] Question: MRD launch strategy - Management indicated a selective approach for the MRD launch, focusing on user experience and operational efficiency before expanding volume [42] Question: Prenatal growth expectations - Management acknowledged a decline in prenatal volume in Q1 but expects recovery in Q2 and beyond, supported by a focused sales team and new product launches [44][76] Question: Prolaris momentum - Management noted that various initiatives, including engagement with KOLs and sales team expansion, contributed to Prolaris' growth, while also acknowledging potential favorable comparisons in Q4 [71][73]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $210 million, exceeding the high end of the pre-announced range, with a year-over-year growth of approximately 4% when excluding the impact from UnitedHealthcare's decision on GeneSight [4][24] - For the full year 2025, total revenue was $824.5 million, with over 1.5 million test reports delivered [6] - Adjusted gross margin for the fourth quarter was 70%, with adjusted EBITDA of $14.3 million and adjusted EPS of $0.04 [7][26] Business Line Data and Key Metrics Changes - Oncology revenue for the fourth quarter was $84.7 million, reflecting a 2% growth year-over-year, with MyRisk test volume growing 14% in the affected market and 11% in the unaffected market [16][18] - Prolaris revenue growth accelerated to 16% year-over-year in the fourth quarter, driven by a 12% increase in test volume [16][17] - Women's health revenue was $88.5 million, a 2% increase year-over-year, with hereditary cancer testing in the unaffected market growing by 3% and volume growth of 11% [18][19] - GeneSight generated revenues of $36.6 million with a 9% year-over-year volume growth [21] Market Data and Key Metrics Changes - The company served over 55,000 healthcare providers, with GeneSight achieving a record number of ordering clinicians exceeding 38,000 [6][21] - The prenatal testing segment experienced a decline in volume due to previous order management disruptions, but recovery is expected in 2026 [20][22] Company Strategy and Development Direction - The company is focusing on high-growth market segments and plans multiple product launches, including the expanded MyRisk panel and AI-enhanced Prolaris test [4][9] - A significant investment of over $35 million is planned to enhance organizational efficiency and commercial capabilities, particularly in cancer care [15][30] - The company aims to strengthen its position across cancer care testing while expanding its commercial capabilities and customer reach [32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving high single-digit to low double-digit growth rates in 2027 and beyond, driven by new product launches and recovery in the prenatal business [39] - The company is optimistic about the ongoing demand for its products and the positive momentum in hereditary cancer testing and GeneSight volumes [23][24] Other Important Information - The company plans to simplify its reporting structure to align with its refreshed strategy, focusing on cancer care continuum, prenatal health, and mental health as distinct categories [30] - The company is preparing for the commercial launch of Precise MRD for breast cancer, with an alpha launch starting next week [12][17] Q&A Session Summary Question: Confidence in long-term growth rate - Management highlighted the drivers of growth for 2026, including product launches and improvements in commercial execution, expressing confidence in returning to high single-digit growth rates [38][39] Question: MRD launch strategy - The company plans to be selective during the alpha phase of the MRD launch, focusing on user experience and operational efficiency before scaling up [41][42] Question: Prenatal growth expectations - Management acknowledged a decline in prenatal volume in Q1 but expects recovery in Q2 and beyond, supported by a focused sales team [44][78] Question: Prolaris momentum and dynamics - Management noted that various initiatives contributed to Prolaris growth, including engagement with key opinion leaders and expansion of the sales team [72][75] Question: GeneSight ASP trends - Management indicated that the trend in average selling price (ASP) for GeneSight is expected to improve as the company engages with payers and secures positive coverage policies [88]

Fourth Quarter and Full Year 2025 Earnings Call F E B R U A R Y 2 3 , 2 0 2 6 ©2026 Myriad Genetics, Inc. Forward-looking statements and Non-GAAP financial measures Some of the information presented here today contains projections or other forward-looking statements regarding future events or the future financial performance of the Company. FORWARD-LOOKING STATEMENTS AND DISCLAIMERS These statements are based on management's current expectations and the actual events or results may differ materially and adv ...

Financial Performance and Guidance - Preliminary Q4 2025 total revenue is expected to be between $207 million and $209 million, and full year 2025 revenue between $822 million and $824 million[51] - Total test volume growth for 2025 is approximately 1% year-over-year, with Hereditary Cancer showing 7% growth, Mental Health 6% growth, and Prenatal Health a (4)% decrease[51] - 2026 total revenue guidance is set at $860 million to $880 million, reflecting approximately 6% growth compared to the midpoint of the preliminary 2025 revenue range[53] - Adjusted gross margin for 2026 is projected to be between 68% and 69%[53] - Adjusted EBITDA for 2026 is expected to be between $37 million and $49 million, representing approximately 43% growth over the midpoint of the previous full year 2025 guidance range[53] - The company is targeting high single-digit to low double-digit percentage annual revenue growth in the long term[60] Strategic Focus and Market Expansion - The company is prioritizing the Cancer Care Continuum to drive accelerated growth and profitability[11, 60] - The company plans to leverage market-leading positions and new products to accelerate growth in markets such as Hereditary Cancer Testing (HCT), therapy selection, prostate cancer, and molecular residual disease (MRD)[13] - The total addressable market (TAM) for therapy selection, HRD (Homologous Recombination Deficiency) & CGP (Comprehensive Genomic Profiling) is estimated at $8 billion, with an estimated annual market growth of 14-17%[13] - The MRD market has a TAM of $21 billion with an estimated annual market growth of 15-20%[13] - The company is expanding its testing menu to serve more of the Cancer Care Continuum, including hereditary cancer screening, diagnosis & therapy selection, and molecular residual disease monitoring[15, 16]

Myriad Genetics FY Conference Summary Company Overview - **Company**: Myriad Genetics (NasdaqGS:MYGN) - **Date of Conference**: December 02, 2025 Key Industry Insights - **Hereditary Cancer Market**: The unaffected population represents a $5 billion market opportunity, with significant growth potential as it remains less than a third penetrated [2][21] - **Mental Health Market**: Myriad Genetics is a market leader in mental health testing, with plans to maintain growth despite challenges from competitors [16][19] Core Company Strategies - **Focus on Cancer Care**: The updated strategy emphasizes a concentrated effort on the cancer care continuum, while managing growth in prenatal and mental health segments [3][8] - **Product Development**: Introduction of new products such as FirstGene and Early Access for prenatal screening, and an updated MyRisk product with 63 genes [7][10] - **Execution Excellence**: Acknowledgment of the need for improved execution in product development and market launch processes [3][4] Financial Performance - **Growth Metrics**: Mid-single-digit growth observed in GeneSight tests, with a return to growth in hereditary cancer testing after previous challenges [6][21] - **Revenue Projections**: GeneSight expected to generate over $150 million in revenue, with potential for mid-single to low double-digit growth rates [16][17] Competitive Landscape - **Market Positioning**: Myriad Genetics aims to differentiate itself from competitors like Natera and BillionToOne by leveraging its comprehensive product offerings and customer support [8][9] - **Guideline Engagement**: Active collaboration with Key Opinion Leaders (KOLs) to clarify NCCN guidelines and enhance the adoption of Myriad's Prolaris test for prostate cancer [12][13] Product Pipeline and R&D Focus - **MRD Testing**: Introduction of the Precise MRD assay, expected to launch in the first half of 2026, with a focus on low-shedding cancers [25][26] - **Partnerships**: Collaborations with Pathomic to accelerate R&D and market entry for new tests [29][33] - **Clinical Studies**: Over 20 studies in MRD across various cancer indications, with results expected to enhance clinical utility and guideline positioning [28][30] Challenges and Opportunities - **Reimbursement Issues**: Navigating reimbursement challenges, particularly with UnitedHealth's policy, while expanding payer coverage [16][20] - **Market Activation**: Efforts to activate the unaffected hereditary cancer market through improved workflows and sales strategies [22][23] Conclusion - Myriad Genetics is strategically positioning itself for growth in the hereditary cancer and mental health markets, with a strong focus on execution excellence and product innovation. The company is optimistic about its future prospects, particularly with the anticipated launch of new products and ongoing collaborations.

Myriad Genetics Conference Call Summary Company Overview - **Company**: Myriad Genetics (NasdaqGS:MYGN) - **Focus Areas**: Precision medicine, hereditary cancer testing, women's health testing, mental health, therapy selection, and minimal residual disease (MRD) [4][6][18] Key Points and Arguments Company Transformation - Myriad Genetics has undergone significant changes over the past year, characterized by positive momentum and a clearer strategy focused on predictable and profitable growth [6][7] - The company aims to grow at or above market rates in prenatal and mental health sectors while prioritizing the cancer care continuum [7][18] - The leadership team has been strengthened with new hires, including a Chief Commercial Officer and a Senior Vice President of Product, to enhance execution and innovation [10][11] Financial Outlook - Myriad targets a high single-digit to low double-digit growth rate over the next three to five years, emphasizing profitability alongside growth [7][14] - The hereditary cancer testing segment is projected to generate approximately $370 million in revenue, accounting for about 45% of total sales, with growth in the low single digits [28] Market Opportunities - The hereditary cancer market is valued at approximately $5 billion, with less than 30% penetration, indicating substantial growth potential [33] - Myriad is expanding its offerings beyond hereditary cancer testing to include therapy selection and MRD, aiming to capture a larger share of the cancer care continuum [18][62] Product Development and Launches - Myriad recently launched an updated MyRisk hereditary cancer panel and plans to introduce several new products over the next 12 months [11] - The company is preparing for the launch of its Precise MRD assay, which aims to differentiate itself through advanced detection capabilities [45][52] Strategic Partnerships - Myriad has formed a partnership with SOPHiA GENETICS and Memorial Sloan Kettering to enhance its liquid biopsy offerings, leveraging their expertise in biomarker discovery and validation [60][61] - The collaboration is expected to ramp up relationships with pharmaceutical partners, facilitating revenue generation ahead of the full commercial launch of MRD [58][60] Internal Metrics and KPIs - Myriad is focused on tracking key performance indicators (KPIs) such as revenue growth, adjusted EBITDA, gross margin, and customer satisfaction metrics to measure success [27][26] - The company is committed to managing resources effectively, ensuring that efforts are concentrated on the cancer care continuum [19][27] Additional Important Insights - Myriad acknowledges the need for a disciplined approach to its portfolio, remaining open to potential changes to optimize its business focus [19][20] - The company is positioning itself to leverage its existing infrastructure and capabilities to accelerate time-to-market for new products [22][23] - Myriad's strategy includes a controlled launch for its MRD assay to ensure proper market adoption and financial management [52][53] This summary encapsulates the key discussions and strategic directions outlined during the Myriad Genetics conference call, highlighting the company's commitment to growth, innovation, and market leadership in the precision medicine space.

Financial Data and Key Metrics Changes - The company reported revenue of $206 million for Q3 2025, a decrease of 4% year-over-year, but a 5% growth when excluding specific headwinds [4][24][26] - Adjusted gross margin was strong at 70.1%, with adjusted EBITDA reported at $10.3 million [6][28] - Test volumes increased by 3%, but average revenue per test decreased by 7% [23][24] Business Line Data and Key Metrics Changes - Oncology revenue was $81.8 million, a decline of 1% year-over-year, with myRisk test volume growth of 16% in the affected market and 11% in the unaffected market [15][19] - Women's health revenue increased by 3% to $85.2 million, with hereditary cancer testing showing a 4% revenue growth and 11% volume growth year-over-year [19][20] - GeneSight revenue was $38.7 million, with an 8% volume growth year-over-year, despite challenges from UnitedHealthcare's coverage policy change [21][22] Market Data and Key Metrics Changes - The hereditary cancer testing market is estimated to be close to $5 billion, with less than 50% penetration, indicating significant growth opportunities [55] - The company is experiencing positive momentum in prenatal testing, with expectations for continued growth following the introduction of the FirstGene test [20][21] Company Strategy and Development Direction - The company is focusing on the cancer care continuum to accelerate growth, leveraging the myRisk test and expanding its portfolio to include other cancer screening and diagnostic tests [7][8] - There is a commitment to grow prenatal health and mental health revenues at or above market growth, with a disciplined investment approach [8][12] - The company is enhancing its commercial capabilities and organizational design to improve customer experience and market share [11][12][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver accelerated profitable growth, emphasizing the importance of operational efficiency and strategic partnerships [9][10][11] - The company is optimistic about the upcoming launches of new products, including an updated myRisk test and the Prolaris prostate cancer test [10][11][18] Other Important Information - The company reaffirmed its full-year 2025 financial guidance, projecting revenue between $818 million and $828 million [30] - The organizational redesign aims to reduce management layers and improve efficiency, which is expected to support revenue growth while controlling operating expenses [29][30] Q&A Session Summary Question: What are the offsets in savings as you go into 2026? - Management reaffirmed a commitment to profitable growth, focusing on the cancer care continuum and reallocating investments to support growth while managing operating expenses [36][37] Question: Any share shift in the NIPT market? - Management acknowledged challenges in operational execution but indicated improvements are being made, with expectations for future growth driven by new products [40][41] Question: Can you provide color on the friction with the new ordering management system? - Management noted that regaining customer volume takes time, but improvements are being made, and they expect to show volume growth in the coming quarters [44][45] Question: What is the current average turnaround time for Prequel results? - Management stated that turnaround times for their products are competitive, emphasizing patient convenience and workflow improvements [68][69] Question: How should we think about ASP assumptions for 2026? - Management highlighted that ASP was impacted by several factors, including changes in payer mix and the divestiture of the EndoPredict business, but they expect positive trends to continue [63][64]

Financial Performance - Q3 2025 revenue was $205.7 million[7], a decrease of 4% year-over-year[33] - Adjusted gross margin in Q3 2025 was 70.1%[7], a decrease of 50 basis points year-over-year[33] - Adjusted EBITDA for Q3 2025 was $10.3 million[7] - Adjusted EPS for Q3 2025 was $0.00[7], a decrease of $0.06 year-over-year[33] - Adjusted operating expenses decreased by $1 million year-over-year in Q3 2025[7] Volume Growth - Hereditary cancer test volume grew 11% year-over-year[8] - GeneSight volume grew 8% year-over-year[8], reflecting ongoing growth acceleration from Q1 '25[30] - Prolaris test volume showed positive growth year-over-year[8] Strategic Initiatives - The company is focused on the Cancer Care Continuum (CCC) to accelerate growth[7, 9, 11] - The company aims to grow revenue at or above market in Prenatal Health and Mental Health[7, 9, 12] - Myriad has commenced a multi-year program to invest >$35 million in its commercial capabilities addressing the Cancer Care Continuum[40] 2025 Financial Guidance - The company reiterates its 2025 financial guidance, with total revenue expected to be between $818 million and $828 million[42] - Gross margin is projected to be between 69.5% and 70.0%[42] - Adjusted operating expenses are expected to be between $562 million and $568 million[42] - Adjusted EBITDA is projected to be between $27 million and $33 million[42] - Adjusted EPS is expected to be between $(0.02) and $0.02[42]

Core Insights - Myriad Genetics reported Q2 2025 earnings with revenue of $213.1 million, surpassing consensus estimates of $201.9 million, but faced a significant impairment charge of $316.7 million leading to a GAAP net loss [1][5][8] - The company experienced a modest return to revenue growth with a year-over-year increase of 1%, and adjusted EPS of $0.05 exceeded analyst expectations of $(0.01) [1][2][5] - The focus on the Cancer Care Continuum strategy emphasizes investment in oncology and next-generation diagnostic testing, with a strong emphasis on R&D and partnerships [4][3] Financial Performance - Revenue for Q2 2025 was $213.1 million, a 0.8% increase from Q2 2024's $211.5 million [2] - Adjusted operating income rose to $8.6 million, a 16.2% increase from Q2 2024 [2][5] - Gross margin improved to 71.2%, up 1.6 percentage points from 69.5% in Q2 2024 [2][5] Segment Performance - The Oncology segment generated $85.5 million in revenue, with hereditary cancer testing contributing $54.1 million, reflecting a 9% year-over-year volume increase [6] - Women's Health reported $89.8 million in revenue, with prenatal testing revenue rising 7% year-over-year to $47.6 million, despite an 8% decline in prenatal test volume due to workflow issues [7] - The Pharmacogenomics segment, including the GeneSight test, posted $37.8 million in revenue, a 12% decrease attributed to the loss of coverage from UnitedHealthcare [8][12] Operational Highlights - Total test volume was 384,000, showing a slight decline from the previous year, with increases in some areas offset by declines in tumor profiling and prenatal tests [9] - The company reported negative adjusted free cash flow of $(17.1) million, compared to a positive figure last year, and cash and equivalents at period end were $74.4 million [10][15] Strategic Focus - Myriad Genetics is prioritizing technological innovation, securing insurance reimbursement, and expanding market presence, particularly in oncology and women's health [4][3] - The company plans to launch new products, including MRD and AI-enabled prostate cancer tests, in 2026 [12] Outlook - Management raised full-year FY2025 revenue guidance to $818 million to $828 million, with gross margin expectations also increased [16] - Adjusted EPS guidance remains between $(0.02) and $0.02 for FY2025, reflecting the second quarter results and current business outlook [16]